Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Daniel

Showing results (1411-1420 of 1,562) with videos related to

Pageof 157
Sort By:
Oncogene|October 24, 2024
KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer developmentSamantha L Tinsley, Ella Rose D Chianis, Rebecca A Shelley, et al.
The Lancet. Microbe|March 13, 2025
Associations of inflammatory markers with post-acute clinical findings among survivors of Ebola virus disease with and without viral RNA shedding in the semen in Liberia: a nested case-control studyMosoka P Fallah, Collin Van Ryn, J Soka Moses, et al.
Medrxiv : the Preprint Server for Health Sciences|July 7, 2021
SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurveyMohamed Bailor Barrie, Sulaiman Lakoh, J Daniel Kelly, et al.
The Ocular Surface|August 12, 2017
TFOS DEWS II Report Executive SummaryJennifer P Craig, J Daniel Nelson, Dimitri T Azar, et al.
JAMA|August 12, 2004
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trialA Michael Lincoff, Neal S Kleiman, Dean J Kereiakes, et al.
Science Translational Medicine|December 13, 2023
A therapeutic strategy to target distinct sources of IgE and durably reverse allergyAndre Limnander, Navneet Kaur, Seblewongel Asrat, et al.
JAMA|February 18, 2003
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialA Michael Lincoff, John A Bittl, Robert A Harrington, et al.
Cancer Research Communications|March 6, 2026
The KRAS-variant and cetuximab in HPV-positive oropharyngeal cancer - results from the NRG/RTOG 1016 trialJoanne B Weidhaas, Jonathan Harris, Maura L Gillison, et al.
The American Journal of Psychiatry|March 3, 2010
Project among African-Americans to explore risks for schizophrenia (PAARTNERS): evidence for impairment and heritability of neurocognitive functioning in families of schizophrenia patientsMonica E Calkins, Ping Tepper, Ruben C Gur, et al.
BMJ Global Health|November 12, 2021
SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurveyMohamed Bailor Barrie, Sulaiman Lakoh, J Daniel Kelly, et al.
Pageof 157

Showing results (1411-1420 of 1,562) with videos related to

Sort By:
Pageof 157
Oncogene|October 24, 2024
KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer developmentSamantha L Tinsley, Ella Rose D Chianis, Rebecca A Shelley, et al.
The Lancet. Microbe|March 13, 2025
Associations of inflammatory markers with post-acute clinical findings among survivors of Ebola virus disease with and without viral RNA shedding in the semen in Liberia: a nested case-control studyMosoka P Fallah, Collin Van Ryn, J Soka Moses, et al.
Medrxiv : the Preprint Server for Health Sciences|July 7, 2021
SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurveyMohamed Bailor Barrie, Sulaiman Lakoh, J Daniel Kelly, et al.
The Ocular Surface|August 12, 2017
TFOS DEWS II Report Executive SummaryJennifer P Craig, J Daniel Nelson, Dimitri T Azar, et al.
JAMA|August 12, 2004
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trialA Michael Lincoff, Neal S Kleiman, Dean J Kereiakes, et al.
Science Translational Medicine|December 13, 2023
A therapeutic strategy to target distinct sources of IgE and durably reverse allergyAndre Limnander, Navneet Kaur, Seblewongel Asrat, et al.
JAMA|February 18, 2003
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialA Michael Lincoff, John A Bittl, Robert A Harrington, et al.
Cancer Research Communications|March 6, 2026
The KRAS-variant and cetuximab in HPV-positive oropharyngeal cancer - results from the NRG/RTOG 1016 trialJoanne B Weidhaas, Jonathan Harris, Maura L Gillison, et al.
The American Journal of Psychiatry|March 3, 2010
Project among African-Americans to explore risks for schizophrenia (PAARTNERS): evidence for impairment and heritability of neurocognitive functioning in families of schizophrenia patientsMonica E Calkins, Ping Tepper, Ruben C Gur, et al.
BMJ Global Health|November 12, 2021
SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurveyMohamed Bailor Barrie, Sulaiman Lakoh, J Daniel Kelly, et al.
Pageof 157